Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable
- Claus Cursiefen1,
- Joseph Colin2,
- Reza Dana3,
- Manuel Diaz-Llopis4,5,6,
- Lana A Faraj7,
- Salvador Garcia-Delpech4,5,6,
- Gerd Geerling8,
- Francis W Price9,
- Lies Remeijer10,
- Barry T Rouse11,
- Berthold Seitz12,
- Patricia Udaondo4,6,
- Daniel Meller13,
- Harminder Dua7
- 1Department of Ophthalmology, University of Cologne, Erlangen, Germany
- 2Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
- 3Massachusetts Eye & Ear Infirmary, Schepens Eye Research Institute, Harvard Medical School, Boston, USA
- 4Department of Ophthalmology, La Fe University Hospital, Valencia, Spain
- 5University of Valencia, Valencia, Spain
- 6Biomedical Network Research Centre on Rare Diseases (CIBERER), Valencia, Spain
- 7Division of Ophthalmology and Visual Sciences, University of Nottingham, Nottingham, UK
- 8Department of Ophthalmology, University of Würzburg, Würzburg, Germany
- 9Price Vision Group and the Cornea Research Foundation of America, Indianapolis, Indiana, USA
- 10Cornea and External Disease Service, The Rotterdam Eye Hospital, Rotterdam, The Netherlands
- 11Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
- 12Department of Ophthalmology, University of Saarland, Homburg, Germany
- 13Department of Ophthalmology, University of Essen, Essen, Germany
- Correspondence to Professor Claus Cursiefen, Department of Ophthalmology, University of Cologne, Joseph-Stelzmann Strasse 9. 50924, Cologne, Germany;
- Accepted 4 June 2011
- Published Online First 28 June 2011
The cornea is the clear window at the front of the eye and is the eye's main refractive medium. Its transparency is essential for vision. Corneal neovascularisation is a common clinical problem with serious consequences for vision; it can compromise corneal transparency and plays a major role in corneal graft rejection by breaching corneal immune privilege. In this review, we formulate a consensus on the unmet medical needs in the management of corneal neovascularisation and outline a framework for the clinical research that is needed to identify suitable agents to meet these needs.
- Corneal neovascularisation
- vascular endothelial growth factor
- clinical trials
- public health
- treatment medical
This Roundtable was conducted during the 5–9 June 2010 World Ophthalmology Congress in Berlin, Germany.
Funding IZKF Erlangen (A9) and Voisin Consulting Life Sciences, France. The planning of this study, interpretation of findings, writing and conclusions of manuscript were undertaken entirely independently of the company interests.
Competing interests CC is a consultant to Gene Signal; all other authors except RD, LAF and DM received travel reimbursement and honoraria from Voisin Consulting Life Sciences, France.
Provenance and peer review Not commissioned; externally peer reviewed.